An Overview of Myelodysplastic Syndrome (MDS)

Patients with AML aged 80 years and older face poor survival despite treatment advances, highlighting the need for improved, equitable care strategies and tailored treatment approaches.

The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from the prespecified interim analysis of the study.

The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy targeting CD38 and developed using the THANK-uCAR platform, in an investigator-initiated trial in China.

LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for recurrent or metastatic head and neck squamous cell carcinoma.

Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, following various risk management measures.

A phase 3 trial of uproleselan in relapsed/refractory acute myeloid leukemia failed to meet the primary overall survival end point but showed a benefit in primary refractory patients.